FDA Releases Final Guidance for Generic Drug Bioequivalence Studies

The FDA has published its final guidance for the industry regarding bioequivalence studies for Abbreviated New Drug Applications (ANDAs). This document offers recommendations for companies submitting bioequivalence data, ensuring compliance with federal regulations. The guidance aims to clarify requirements for generic drug approvals.